Key result
Trimetazidine and trimethylhydrazine optimize energy supply and metabolism, demonstrating efficacy in the complex therapy of cardiovascular and cerebrovascular diseases in elderly patients.
Why the study?
Do metabolic cardiocytoprotectors (trimetazidine and trimethylhydrazine) improve clinical outcomes in elderly patients with cardiovascular and cerebrovascular diseases?
Do metabolic cardiocytoprotectors (trimetazidine and trimethylhydrazine) improve clinical outcomes in elderly patients with cardiovascular and cerebrovascular diseases?
Metabolic cardiocytoprotectors like trimetazidine and trimethylhydrazine show promise as adjunctive therapies for cardiovascular and cerebrovascular diseases in geriatric patients by optimizing myocardial and cerebral energy metabolism.
Answers are grounded in this paper and cite their sources.
May support adjunctive trimetazidine in elderly cardiovascular care; hypothesis-generating and requires randomized confirmation.
The review presents the clinical studies results of the effectiveness of cardiocytoprotectors, fatty acids synthesis inhibitors, trimetazidine (preductal), and trimethylhydrazine (meldonium, mildronate) in the treatment of cardiovascular disease (angina pectoris, chronic heart failure) and the central nervous system disease (dyscirculatory encephalopathy, chronic cerebral insufficiency, stroke) various ages patients. These data indicate the prospects of using these drugs in the complex therapy of cardiovascular and cerebrovascular diseases in the geriatric clinic.
No takes yet. Share an insight, caveat, or question.
Kuprash et al. (2022) conducted a review in Cardiovascular and cerebrovascular diseases. Trimetazidine and trimethylhydrazine was evaluated. Trimetazidine and trimethylhydrazine optimize energy supply and metabolism, demonstrating efficacy in the complex therapy of cardiovascular and cerebrovascular diseases in elderly patients.
Synapse has enriched 10 related papers. Consider them for comparative context: